U. H. Gandhi, R. F. Cornell, A. Lakshman, Z. J. Gahvari, E. Mcgehee et al., Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, Leukemia, vol.33, pp.2266-75, 2019.

N. Bolli, H. Avet-loiseau, D. C. Wedge, P. Van-loo, L. B. Alexandrov et al., Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat Commun, vol.5, p.2997, 2014.

E. M. Boyle, C. Ashby, R. Tytarenko, S. Deshpande, Y. Wang et al., BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma, Clin Cancer Res, 2020.

M. A. Chapman, M. S. Lawrence, J. J. Keats, K. Cibulskis, C. Sougnez et al., Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, pp.467-72, 2011.

M. Lionetti, M. Barbieri, K. Todoerti, L. Agnelli, S. Marzorati et al., Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, vol.6, pp.24205-24222, 2015.

M. Andrulis, N. Lehners, D. Capper, R. Penzel, C. Heining et al., Targeting the BRAF V600E mutation in multiple myeloma, Cancer Discov, vol.3, pp.862-871, 2013.

M. C. Da-vià, A. G. Solimando, A. Garitano-trojaola, S. Barrio, U. Munawar et al., CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement

. Oncologist, , 2019.

U. Mey, C. Renner, and R. Von-moos, Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation, Hematol Oncol, vol.35, pp.890-893, 2017.

M. S. Raab, N. Lehners, J. Xu, A. D. Ho, P. Schirmacher et al., Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition, Blood, vol.127, pp.2155-2162, 2016.

J. P. Sharman, J. Chmielecki, D. Morosini, G. A. Palmer, J. S. Ross et al., Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma, Clin Lymphoma Myeloma Leuk, vol.14, pp.161-164, 2014.

G. V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. De-braud et al., Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, vol.371, pp.1877-88, 2014.

R. Nazarian, H. Shi, Q. Wang, X. Kong, R. C. Koya et al., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-980, 2010.

S. J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-duvas et al., Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, vol.140, pp.209-230, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02122069

D. Regno, L. Louveau, B. Battistella, M. Sadoux, A. Baroudjian et al.,

J. , Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort, Br J Dermatol, 2019.

S. Pasca, C. Tomuleasa, P. Teodorescu, G. Ghiaur, D. Dima et al., KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma, Front Oncol, vol.9, p.1137, 2019.

L. Calvez, B. , L. Bris, Y. Herbreteau, and G. , RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation